In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Al Ejeh, Fares ^a   Darby, Jocelyn M ^a   Pensa, Katherine ^a   Diener, Kerrilyn R ^a   Hayball, John D ^a,b   Brown, Michael P ^a,c  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; AUTOANTIGEN; CARBON 14; CYCLOPHOSPHAMIDE; ETOPOSIDE; INDIUM 111; LA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3B9; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; DRUG DISTRIBUTION; DRUG TARGETING; ISOTOPE LABELING; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR SCINTISCANNING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOANTIGENS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DNA DAMAGE; ETOPOSIDE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RADIOIMMUNOTHERAPY; RIBONUCLEOPROTEINS; THYMUS GLAND; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848886657     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0964     Document Type: Conference Paper

References (51)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
3. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000;6:4610-7.
4. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
5. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 2003;9:955-60.
6. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
7. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004;31:887-919.
8. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A, Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42.
9. Collingridge DR, Glaser M, Osman S, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of Annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003;89:1327-33.
10. van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC Annexin V single photon emission computed tomography. J Clin Oncol 2003;21:3483-7.
11. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 1998;95:6349-54.
12. 99mTc- annexin V. J Nucl Med 2003;44:92-7.
13. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-74.
14. Jain D, Crawley JC, Lahiri A, Raftery EB. Indium-111-antimyosin images compared with triphenyl tetrazolium chloride staining in a patient six days after myocardial infarction. J Nucl Med 1990;31:231-3.
15. Tamaki N, Yamada T, Matsumori A, et al. Indium-111-antimyosin antibody imaging for detecting different stages of myocardial infarction: comparison with technetium-99m-pyrophosphate imaging. J Nucl Med 1990;31:136-42.
16. Matsumori A, Yamada T, Tamaki N, et al. Persistent uptake of indium-111-antimyosin monoclonal antibody in patients with myocardial infarction. Am Heart J 1990;120:1026-30.
17. Kairemo KJ, Wiklund TA, Liewendahl K, et al. Imaging of soft-tissue sarcomas with indium-111-labeled monoclonal antimyosin Fab fragments. J Nucl Med 1990;31:23-31.
18. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7.
19. Deb N, Goris M, Trisler K, et al. Treatment of hormone refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996;2:1289-97.
20. Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842-8.
21. Miller GK, Naeve GS, Gaffar SA, Epstein AL. Immunologic and biochemical analysis of TNT-1and TNT-2 monoclonal antibody binding to histones. Hybridoma 1993;12:689-98.
22. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm 2002;17:359-70.
23. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005;23:1538-47.
24. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A 2004;101:14865-70.
25. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001;7:1241-4.
26. Lu CM, Burton WD, Fitzgerald RL, et al. Mass spectrometric immunoassay for parathyroid hormone-related protein. Anal Chem 2002;74:5507-12.
27. Al-Ejeh F, Darby J, Brown MP. Methods for optimizing radioimmunoconjugates and their effects on antibody activity. Cancer Biother Radiopharm 2006;21:400.
28. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992;3:342-5.
29. Brady ED, Chong HS, Milenic DE, Brechbiel MW. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. Nucl Med Biol 2004;31:795-802.
30. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands inmacrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977-82.
31. Liu S, Edwards DS. Synthesis and characterization of two (111) In-labeled DTPA-peptide conjugates. Bioconjug Chem 2001;12:630-4.
32. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001;12:7-34.
33. Liu S, Edwards DS. Stabilization of (90)y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem 2001;12:554-8.
34. Liu S, Harris TD, Ellars CE, Edwards DS. Anaerobic 90Y-and 177Lu-labeling of a DOTA-conjugated non-peptide vitronectin receptor antagonist. Bioconjug Chem 2003;14:1030-7.
35. 111In-labeled DOTA-biomolecule conjugates. Inorg Chem 2003;42:8831-7.
36. Liu S, Ellars CE, Edwards DS. Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradio-pharmaceuticals. Bioconjug Chem 2003;14:1052-6.
37. Grabarek J, Ardelt B, Kunicki J, Darzynkiewicz Z. Detection of in situ activation of transglutaminase during apoptosis: correlation with the cell cycle phase by multiparameter flow and laser scanning cytometry. Cytometry 2002;49:83-9.
38. Beller GA, Khaw BA , Haber E, Smith TW. Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate. Circulation 1977;55:74-8.
39. Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction. Histologic, histochemical, autoradiographic and scintigraphic studies. Circulation 1979;60:1527-31.
40. 131I-labeled TNT-1monoclonal antibody. Cancer Res 1989;49:4578-85.
41. Hornick JL, Sharifi J, Khawli LA, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13:255-68.
42. Hornick JL, Sharifi J, Khawli LA, et al. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med 2000;41:355-62.
43. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
44. Lazo JS. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol 1986;35:1919-23.
45. Albrecht H, DeNardo SJ. Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm 2006;21:285-304.
46. Goldenberg DM. Cancer imaging with CEA antibodies: historical and current perspectives. Int J Biol Markers 1992;7:183-8.
47. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002;99:13765-70.
48. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
49. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
50. Reed JC. Drug insight: Cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006;3:388-98.
51. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.